Novartis Ag · SIX:NOVN
Novartis — Q3 2022 Earnings Presentation
95 slides from Novartis's earnings presentation, Oct 25, 2022
Slide 1: Q3 2022 Results Investor presentation
Company overview Financial review 2022 priorities Appendix References Q3 2022 Results Investor presentation 1 Investor Relations │ Q3 2022 Results
Slide 2: Disclaimer
Company overview Financial review 2022 priorities Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,”
Slide 3: Company overview - Vas Narasimhan, CEO
Company Company overview overview Financial review 2022 priorities Appendix References Vas Narasimhan Chief Executive Officer Company overview 3 NOVARTIS Q3 RESULTS | OCTOBER 25, 2022 | NOVARTIS INVESTOR PRESENTATION 3 Investor Relations │ Q3 2022 Results
Slide 4: Novartis delivers solid Q3 performance across our value drivers
Company Company overview overview Financial review 2022 priorities Appendix References Novartis delivers solid Q3 performance across our value drivers Growth, cc 1 Innovation 3 Group sales Q3 +4% (YTD +5%) Scemblix approved in EU for Ph+ chronic myeloid leukemia IM sales Q3 +4% (YTD +5%); US IM sale
Slide 5: Strong performance of Entresto, Kesimpta, Kisqali, Pluvicto
Company Company overview overview Financial review 2022 priorities Appendix References 1 GROWTH Strong performance of Entresto®, Kesimpta®, Kisqali ®, Pluvicto® Q3 sales1 Sales Growth vs. PY Growth vs. PY USD million USD million cc 1,135 211 31% 289 180 172% 327 95 49% 80 80 nm 41 41 nm 450 33 16% 3
Slide 6: 33% of IM sales growing 23% (Q3)
Company Company overview overview Financial review 2022 priorities Appendix References 1 GROWTH Six in-market growth drivers with multi-bn sales potential and recent launches reinforce our confidence in mid-term growth outlook 6 in-market growth drivers, multi-bn potential 33% of IM sales growing 23
Slide 7: Cosentyx showed steady growth, preparing for LCM
Company Company overview overview Financial review 2022 priorities Appendix References 1 GROWTH Cosentyx® showed steady growth, preparing for LCM Sales evolution USD m, % cc Maintaining competitive position across geographies Ex-US § >875k patients treated across 5 indications since launch US +7% cc
Slide 8: Entresto +31% cc, growing strongly across geographies
Company Company overview overview Financial review 2022 priorities Appendix References 1 GROWTH Entresto® +31% cc, growing strongly across geographies Sales evolution US weekly TRx1 USD m, % cc Total prescriptions (000) Strong quarter performance Ex-US 100 § WW: Increased to >8m patients on treatmen
Slide 9: Zolgensma sales now predominantly incident patient population
Company Company overview overview Financial review 2022 priorities Appendix References Zolgensma® sales now predominantly incident patient population Sales evolution USD m Ex-US US 379 § Both US and ex-US market now mainly incident patient population 375 363 342 § YTD double digit growth in incident
Slide 10: Kisqali grows strongly across all regions
Company Company overview overview Financial review 2022 priorities Appendix References 1 GROWTH Kisqali® grows strongly across all regions Increasing recognition of overall survival and quality of life benefits Sales evolution mBC monthly % NBRx share USD m, % cc § Sales accelerating: US NBRx Verzen
Slide 11: Kesimpta strong sales growth driven by US launch momentum
Company Company overview overview Financial review 2022 priorities Appendix References 1 GROWTH Kesimpta® strong sales growth mainly driven by US launch momentum Sales evolution USD m, % cc Ex-US +172% Launch acceleration continues1 US § TRx +131% 289 § NBRx +47% vs. market -20% 239 § B-cell NBRx sh
Slide 12: Leqvio US launch – steadily building the foundation
Company Company overview overview Financial review 2022 priorities Appendix References 1 GROWTH Leqvio® US launch – steadily building the foundation Expect continued steady ramp through H1 2023 Driving broad HCP adoption HCPs initiating a patient1 on Leqvio® ~4800 § Q3 sales USD 34m § HCP adoption d
Slide 13: Pluvicto continues strong start in the US
Company Company overview overview Financial review 2022 priorities Appendix References 1 GROWTH Pluvicto™ continues strong start in the US Rapid launch uptake in US Preparing for further expansion Q3 sales of USD 80m; NBRx share 14% Steadily expanding treatment centers in the US in post-taxane mCRPC
Slide 14: Scemblix continues strong launch momentum in Q3
Company Company overview overview Financial review 2022 priorities Appendix References 1 GROWTH Scemblix® continues strong launch momentum in Q3 Strong early launch uptake Future growth drivers $41m Q3 sales driven by patients with US Accelerated approval converted to resistance/intolerance to other
Slide 15: Cosentyx – efficacy in Hidradenitis Suppurativa up to 52 weeks
Company Company overview overview Financial review 2022 priorities Appendix References 3 INNOVATION Cosentyx® – rapid and sustained efficacy in Hidradenitis Suppurativa up to 52 weeks High unmet need Cosentyx® Ph3 data (SUNSHINE, SUNRISE)4 Rapid from pain, people affected relief flares, lesions, ~1
Slide 16: PNH first pivotal read-out for iptacopan
Company Company overview overview Financial review 2022 priorities Appendix References 3 INNOVATION PNH first pivotal read-out for iptacopan “pipeline in a pill” with combined multi-blockbuster potential Indication 2021 2022 2023 2024 2025 2026 Paroxysmal nocturnal hemoglobinuria PNH (PNH) Phase 3 t
Slide 17: APPLY-PNH demonstrated superiority vs. anti-C5
Company Company overview overview Financial review 2022 priorities Appendix References 3 INNOVATION APPLY-PNH demonstrated clinically meaningful superiority vs. anti-C5 LNP023 200mg BID Continue with Population (n = 97) LNP023 (n= 62) 200mg BID Adult PNH patients with residual anemia (Hb Anti-C5 ant
Slide 18: Iptacopan potential first line oral complement inhibitor in PNH
Company Company overview overview Financial review 2022 priorities Appendix References 3 INNOVATION Iptacopan has the potential to be a first line, oral complement inhibitor mono-therapy in patients with PNH Unmet need in PNH1-5 Iptacopan PNH value proposition 10-20 cases/million; US 4-6k Addresses
Slide 19: Sandoz delivers another quarter of growth
Company Company overview overview Financial review 2022 priorities Appendix References 1 GROWTH Sandoz delivers another quarter of growth Driven by Biopharma and ex-US sales Growth rates Q3 sales Solid top line growth; 4th consecutive quarter In cc % cc, USD bn Maintaining § Russia/Ukraine impact of
Slide 20: Financial review and 2022 guidance - Harry Kirsch, CFO
Company overview Financial review Financial review 2022 priorities Appendix References Harry Kirsch Chief Financial Officer Financial review and 2022 guidance 20 NOVARTIS Q3 RESULTS | OCTOBER 25, 2022 | NOVARTIS INVESTOR PRESENTATION 20 Investor Relations │ Q3 2022 Results
Slide 21: Solid Q3 and YTD performance
Company overview Financial review Financial review 2022 priorities Appendix References Solid Q3 and YTD performance Group1 Q3 Change vs. PY 9M Change vs. PY USD million 2022 % USD % cc 2022 % USD % cc Net Sales 12,543 -4 4 37,855 -1 5 Core Operating income 4,282 -4 5 12,635 -1 6 Operating income 2,1
Slide 22: Continuing core margin improvements for Group driven by IM
Company overview Financial review Financial review 2022 priorities Appendix References Continuing core margin improvements for Group driven by IM Q3 2022 9M 2022 Core operating Core operating Net sales 1 Core margin Net sales 1 Core margin income Core margin income Core margin change vs. PY change v
Slide 23: On track to deliver operational efficiencies
Company overview Financial review Financial review 2022 priorities Appendix References On track to deliver operational efficiencies Savings of ~USD 1.5bn to be fully embedded by 2024 ~USD 1.5bn Integrated Operations unit synergies One-time restructuring cost Simplification of M&S structure estimated
Slide 24: 2022 full year guidance
Company overview Financial review Financial review 2022 priorities Appendix References 2022 full year guidance Expected, barring unforeseen events; growth vs. PY in cc Innovative Sales to grow mid single digit Medicines Core OpInc to grow mid to high single digit, ahead of sales Sales to grow low to
Slide 25: FY 2022 guidance on other financial KPIs
Company overview Financial review Financial review 2022 priorities Appendix References FY 2022 guidance on other financial KPIs Barring unforeseen events; growth vs. PY in cc Group | full year guidance vs. PY (cc) Core Net Expenses expected to decrease by around 100-150m vs. 2021 Financial Result (r
Slide 26: Expected currency impact for full year 2022 and 2023
Company overview Financial review Financial review 2022 priorities Appendix References Expected currency impact for full year 2022 and 2023 Currency impact vs. PY %pts, assuming late October exchange rates prevail in 2022 and 2023 FX impact on Net sales FX impact on Core operating income 2 2 -4 -4 -
Slide 27: 2022 priorities - Vas Narasimhan
Company overview Financial review 2022 2022 priorities priorities Appendix References Vas Narasimhan Chief Executive Officer 27 NOVARTIS Q3 RESULTS | OCTOBER 25, 2022 | NOVARTIS INVESTOR PRESENTATION 27 Investor Relations │ Q3 2022 Results
Slide 28: New Novartis: Our strategy
Company overview Financial review 2022 2022 priorities priorities Appendix References New Novartis: Our strategy Deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches Our focus Our priorities 5 core Therapeutic
Slide 29: Novartis maintains growth momentum, confirms FY 2022 guidance
Company overview Financial review 2022 2022 priorities priorities Appendix References Novartis maintains growth momentum, confirms FY 2022 guidance Top 2022 priorities on track 1 Successful launches: Leqvio (laying the foundation), Kesimpta, Pluvicto, Scemblix 2 Maintain growth momentum: 3 Progress
Slide 30: Appendix
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Appendix 30 Investor Relations │ Q3 2022 Results
Slide 31: Net debt increased by USD 6.8bn
Company overview Financial review 2022 priorities Appendix Appendix References Financial Financial performance performance Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Net debt increased by USD 6.8bn mainly due to dividends and share buybacks, partially offset by FCF (USD
Slide 32: Broad pipeline of novel medicines continued to evolve in Q3
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Broad pipeline of novel medicines continued to evolve in Q3 Core therapeutic areas Cardiovascular
Slide 33: 2022 events (expected)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations 2022 events1 (expected) ✓ Achieved to plan ✕ Not achieved to plan NME Lead Regulatory H1 Pluvicto
Slide 34: Confident in future growth: cardiovascular, immunology, neuroscience
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Confident in future growth driven by our strength and depth in cardiovascular, immunology, neuros
Slide 35: ... and strength and depth in oncology
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations ... and strength and depth in oncology Selected assets, nearly all with exclusivity into 2030+ So
Slide 36: Our pipeline projects at a glance
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Our pipeline projects at a glance Phase 1/2 Phase 3 Registration Total Innovative medicines 97 44
Slide 37: Novartis pipeline in Phase 1
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Novartis pipeline in Phase 1 30 lead indications Lead indication Solid tumors Hematology Code Nam
Slide 38: Novartis pipeline in Phase 2
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Novartis pipeline in Phase 2 27 lead indications Lead indication Solid Tumors Hematology Code Nam
Slide 39: Novartis pipeline in Phase 3
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Novartis pipeline in Phase 3 9 lead indications Lead indication Solid Tumors Hematology Code Name
Slide 40: Novartis pipeline in registration
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Novartis pipeline in registration 1 lead indication Lead indication Solid Tumors Cardiovascular C
Slide 41: Novartis submission schedule: new molecular entities
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Novartis submission schedule New Molecular Entities: Lead and supplementary indications 2022 2023
Slide 42: Submission schedule: existing brands
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Novartis submission schedule Supplementary indications for existing brands 2022 2023 2024 2025 ≥2
Slide 43: Clinical Trials Update
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Clinical Trials Update Includes selected ongo
Slide 44: Cardiovascular
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Cardiovascular 44 Investor Relations │ Q3 202
Slide 45: iptacopan - CFB inhibitor (C3G, iMN)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor iptacopan - CFB inh
Slide 46: iptacopan - CFB inhibitor (APPLAUSE-IgAN, APPEAR-C3G)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor iptacopan - CFB inh
Slide 47: Leqvio - siRNA (ORION-4, ORION-8)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) Leqvio®
Slide 48: Leqvio - siRNA (ORION-16, ORION-13)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) Leqvio®
Slide 49: Leqvio - siRNA (VICTORION-2P)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) NCT0503
Slide 50: pelacarsen - ASO targeting Lp(a)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other pelacarsen - ASO targeting Lp(a) NCT04023552
Slide 51: Immunology
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Immunology 51 Investor Relations │ Q3 2022 Re
Slide 52: Cosentyx - IL-17A inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Cosentyx® - IL-17A inhibitor Cosentyx® - IL-1
Slide 53: ianalumab - BAFF-R inhibitor (AMBER, SIRIUS-LN)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF
Slide 54: ianalumab - BAFF-R inhibitor (NEPTUNUS)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF
Slide 55: iscalimab - CD40 inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iscalimab - CD40 inhibitor NCT03905525 TWINSS
Slide 56: ligelizumab - IgE Inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ligelizumab - IgE Inhibitor NCT04984876 (CQGE
Slide 57: LNA043 - ANGPTL3 agonist
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other LNA043 - ANGPTL3 agonist NCT04864392 ONWARDS
Slide 58: remibrutinib - BTK inhibitor (CSU)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other remibrutinib - BTK inhibitor remibrutinib - B
Slide 59: Neuroscience
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Neuroscience 59 Investor Relations │ Q3 2022
Slide 60: branaplam - mRNA splicing modulator
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other branaplam - mRNA splicing modulator NCT051112
Slide 61: Mayzent - S1P1,5 receptor modulator
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Mayzent® - S1P1,5 receptor modulator NCT04926
Slide 62: MIJ821 - NR2B negative allosteric modulator
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other MIJ821 - NR2B negative allosteric modulator (
Slide 63: remibrutinib - BTK inhibitor (MS)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other remibrutinib - BTK inhibitor remibrutinib - B
Slide 64: Zolgensma - SMN1 gene replacement therapy
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Zolgensma® - SMN1 gene replacement therapy Zo
Slide 65: Oncology
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Oncology 65 Investor Relations │ Q3 2022 Resu
Slide 66: iptacopan - CFB inhibitor (APPLY-PNH, APPOINT-PNH)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor iptacopan - CFB inh
Slide 67: iptacopan - CFB inhibitor (APPELHUS)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor NCT04889430 APPELHU
Slide 68: Jakavi - JAK1/2 inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Jakavi® - JAK1/2 inhibitor Jakavi® - JAK1/2 i
Slide 69: JDQ443 - KRAS inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other JDQ443 - KRAS inhibitor NCT05132075 KontRASt-
Slide 70: Kisqali - CDK4 inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Kisqali® - CDK4 inhibitor NCT03701334 NATALEE
Slide 71: NIS793 - TGFβ inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other NIS793 - TGFβ inhibitor NCT04935359 daNIS-2 (
Slide 72: Piqray - PI3K-alpha inhibitor (EPIK-B2, EPIK-B3)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Piqray® - PI3K-alpha inhibitor Piqray® - PI3K
Slide 73: Piqray - PI3K-alpha inhibitor (EPIK-O)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Piqray® - PI3K-alpha inhibitor NCT04729387 EP
Slide 74: Pluvicto - Radioligand therapy target PSMA
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Pluvicto® - Radioligand therapy target PSMA P
Slide 75: Promacta - Thrombopoetin receptor agonist
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Promacta® - Thrombopoetin receptor agonist Pr
Slide 76: Rydapt - Multi-targeted kinase inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Rydapt® - Multi-targeted kinase inhibitor NCT
Slide 77: sabatolimab - TIM3 antagonist (STIMULUS MDS-1, AML1)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other sabatolimab - TIM3 antagonist sabatolimab - T
Slide 78: sabatolimab - TIM3 antagonist (STIMULUS-MDS2)
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other sabatolimab - TIM3 antagonist NCT04266301 STI
Slide 79: Scemblix - BCR-ABL inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Scemblix® - BCR-ABL inhibitor NCT04971226 ASC
Slide 80: Tabrecta - Met inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Tabrecta® - Met inhibitor NCT04427072 (CINC28
Slide 81: TNO155 - SHP2 inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other TNO155 - SHP2 inhibitor NCT03114319 (CTNO155X
Slide 82: Other
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Health Biosimilars Other
Slide 83: Ophthalmology
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Ophthalmology Global Health Bio
Slide 84: Beovu - VEGF Inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Ophthalmology Global Health Bio
Slide 85: libvatrep - TRPV1 antagonist
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Ophthalmology Global Health Bio
Slide 86: UNR844 - Reduction of disulfide bonds
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Ophthalmology Global Health Bio
Slide 87: Global Health
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Bio
Slide 88: Adakveo - P-selectin inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Bio
Slide 89: cipargamin - PfATP4 inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Bio
Slide 90: Coartem - PGH-1
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Bio
Slide 91: ganaplacide - Imidazolopiperazines derivative
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Bio
Slide 92: Biosimilars
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Health Biosimilars Biosi
Slide 93: aflibercept - VEGF inhibitor
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Bio
Slide 94: Abbreviations
Company overview Financial review 2022 priorities Appendix Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Abbreviations Abbreviations aBC Advanced breast cancer HF-rEF Chronic heart failure with reduced ejection fraction AD Atopic De
Slide 95: References
Company overview Financial review 2022 priorities Appendix References References References Entresto® 1 IQVIA National Prescription Audit as of Sep ’22. 2 Eligible patients defined as prevalent HFrEF patients within each market’s label. G7: US, CA, JP, DE, FR, IT, UK/ 3 Zhang et al., ESC Heart Failu